Management of advanced ovarian cancer in Spain: an expert Delphi consensus
Andres Redondo 1 , Ana Oaknin 2 , Maria Jesus Rubio 3 , Maria-Pilar Barretina-Ginesta 4 , Ana de Juan 5 , Luis Manso 6 , Ignacio Romero 7 , Cristina Martin-Lorente 8 , Andres Poveda 9 , Antonio Gonzalez-Martin 10
Background: To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with a group of Spanish gynecologists and medical oncologists specially dedicated to gynecological tumors.
Methods: The questionnaire was developed by the byline authors. All questions but one were answered using a 9-item Likert-like scale with three types of answers: frequency, relevance and agreement. We performed two rounds between December 2018 and July 2019. A consensus was considered reached when at least 75% of the answers were located within three consecutive points of the Likert scale.
Results: In the first round, 32 oncologists and gynecologists were invited to participate, and 31 (96.9%) completed the online questionnaire. In the second round, 27 (87.1%) completed the online questionnaire.
The results for the questions on first-line management of advanced disease, treatment of patients with recurrent disease for whom platinum might be the best option, and treatment of patients with recurrent disease for whom platinum might not be the best option are presented.
Conclusions: This survey shows a snapshot of current recommendations by this selected group of physicians. Although the majority of the agreements and recommendations are aligned with the recently published ESMO-ESGO consensus, there are some discrepancies that can be explained by differences in the interpretation of certain clinical trials, reimbursement or accessibility issues.
CITA DEL ARTICULO J Ovarian Res. 2021 May 26;14(1):72. doi: 10.1186/s13048-021-00816-x